Cargando…
Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics
Waldenström's macroglobulinemia (WM) is a rare, low-grade malignancy with no established standard of care. Rituximab regimens are most commonly used, supported by their efficacy in hematologic malignancies, including WM. A growing number of investigational regimens for WM have been evaluated in...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722893/ https://www.ncbi.nlm.nih.gov/pubmed/26598544 http://dx.doi.org/10.1093/annonc/mdv572 |